ClinicalTrials.gg
RecruitingNCT07846280Updated Nov 16, 2026

Study to Assess the Long-term Safety of KN3835 in the Treatment and Retreatment of Flexible/Semi-Flexible Hammertoe (HMT)

A Phase 3 interventional study of KN3835 in Flexible Hammertoe and Semi-flexible Hammertoe, sponsored by Endo USA Inc., a Keenova Therapeutics Company. Recruiting at 4 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Endo USA Inc., a Keenova Therapeutics Company (part of Keenova Therapeutics plc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 16, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
470
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The primary purpose of this study is to assess the long-term safety of treatment and retreatment with KN3835 for flexible/semi-flexible HMT.

Read the detailed description

This extension study is for eligible participants who completed parent study KN3835-313 HMT. The study comprises 2 parts:

  • Part I: a double-blind Observation Period from Observational Day 1 to Observational Day 360, and
  • Part 2: an optional open-label Treatment/Retreatment Period from Observational Day 180 (Treatment/Retreatment Day 1) to Treatment/Retreatment Day 360 (End of Study).
02

Conditions studied

  • Flexible Hammertoe
  • Semi-flexible Hammertoe
03

In context

Lead sponsor

Endo USA Inc., a Keenova Therapeutics Company is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Were enrolled in and completed Study KN3835-313 (participants who completed the study are those that completed the Day 57/End of Study Visit, were assessed for safety, and received at least 1 dose of study intervention).
  • Has no significant medical history or examination findings related to the foot to be treated, which in the investigator's opinion, would make the participant unsuitable for study intervention administration or study required evaluations.
  • If female, be of non- or, if of childbearing potential, be non-pregnant, non-lactating and agree to use effective when with a male partner for the duration of the study and for 28 days after treatment.
  • Be willing and able to comply with all protocol required visits and assessments.

Key Exclusion Criteria:

  • Has any significant medical condition, or a serious or severe event in the parent study or any ongoing event from the parent study, which in the investigator's opinion, would make the participant unsuitable for enrollment in the study.
  • Has received or plans to receive surgical or nonsurgical treatments on the foot or toe that was treated for the duration of study participation.

Note: Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
470 participants (estimated)

Study arms

  • Experimental
    Observation then KN3835

    After observation during Part 1 of the study, participants will have the option to receive treatment or retreatment with KN3835 in Part 2.

    Biological: KN3835

  • No intervention
    Observation Only

    Participants will be observed through Part 1. After completion of Part 1, participants will have the option to be observed only during Part 2 of the study.

Interventions

  • BiologicalKN3835

    Participants will receive KN3835 in Part 2 of the Study

    Also known as: EN3835

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events

    Time frame: Observational Day 1 up to Treatment/Retreatment Period Day 360

Secondary outcomes

  1. Change from Baseline In Foot Function Index (FFI) Total Score In Part 1 Observational Period

    Time frame: Baseline and up to Observational Day 360

  2. Change from Baseline In FFI Subscales (Difficulty, Pain and Activity Limitation) Scores In Part 1 Observational Period

    Time frame: Baseline and up to Observational Day 360

  3. Change from Baseline In Pain Intensity Numeric Rating Scale (NRS) Score In Part 1 Observational Period

    Time frame: Baseline and up to Observational Day 360

  4. Percentage of Participants That Meet Retreatment/Treatment Criteria In Part 1 Observational Period

    Time frame: Observational Day 180

  5. Percentage of Participants Reporting To Be "Quite Satisfied" and "Very Satisfied" On The Subject Satisfaction With Treatment Scale In Part 1 Observational Period

    Time frame: Up to Observational Day 360

  6. Percentage Participants with Investigator Reported "Minimal Improvement", "Much Improvement", or "Very Much Improvement" on the Clinician Global Impression of Change Scale (CGIC) Scale Score in Part 1 Observational Period

    Time frame: Up to Observational Day 360

  7. Change from Baseline In Flexion Contracture As Measured By Goniometer in Part 1 Observational Period

    Time frame: Baseline and up to Observational Day 360

  8. Percent Change from Baseline In Flexion Contracture As Measured By Goniometer in Part 1 Observational Period

    Time frame: Baseline and up to Observational Day 360

  9. Change from Baseline In The Patient Global Impression of Severity (PGIS) HMT Overall Scale Score in Part 1 Observational Period

    Time frame: Baseline and up to Observational Day 360

  10. Percentage Of Participants reporting "Minimal Improvement", "Much Improvement", or "Very Much Improvement" on the Patient Global Impression of Change Scale (PGIC) HMT Overall Scale Score in Part 1 Observational Period

    Time frame: Up to Observational Day 360

  11. Change from Baseline In FFI Total Score In Part 2 Treatment/Retreatment Period

    Time frame: Baseline and up to Treatment/Retreatment Period Day 360

  12. Change from Baseline In FFI Subscales (Difficulty, Pain and Activity Limitation) Scores In Part 2 Treatment/Retreatment Period

    Time frame: Baseline and up to Treatment/Retreatment Period Day 360

  13. Change from Baseline In Pain Intensity NRS Score In Part 2 Treatment/Retreatment Period

    Time frame: Baseline and up to Treatment/Retreatment Period Day 360

  14. Percentage of Participants Reporting To Be "Satisfied" and "Very Satisfied" On The Subject Satisfaction With Treatment Scale In Part 2 Treatment/Retreatment Period

    Time frame: Up to Treatment/Retreatment Period Day 360

  15. Percentage Of Participants with Investigator Reported "Minimal Improvement", "Much Improvement", or "Very Much Improvement" on the CGIC HMT Overall Scale Score in Part 2 Treatment/Retreatment Period

    Time frame: Up to Treatment/Retreatment Period Day 360

  16. Change from Baseline In Flexion Contracture As Measured By Goniometer in Part 2 Treatment/Retreatment Period

    Time frame: Baseline and up to Treatment/Retreatment Period Day 360

  17. Percent Change from Baseline In Flexion Contracture As Measured By Goniometer in Part 2 Treatment/Retreatment Period

    Time frame: Baseline and up to Treatment/Retreatment Period Day 360

  18. Change from Baseline In The PGIS HMT Overall Scale Score in Part 2 Treatment/Retreatment Period

    Time frame: Baseline and up to Treatment/Retreatment Period Day 360

  19. Percentage Of Participants reporting "Minimal Improvement", "Much Improvement", or "Very Much Improvement" on the PGIC HMT Overall Scale Score in Part 2 Treatment/Retreatment Period

    Time frame: Up to Treatment/Retreatment Period Day 360

07

Study locations

4 of 4 sites recruiting
  • Keenova Site-008
    Tarzana, California 91356, United States
    Recruiting
    • Fardin Hakakian · Principal investigator
  • Keenova Site-004
    Pinellas Park, Florida 33782, United States
    Recruiting
    • Jason Levy · Principal investigator
  • Keenova Site-007
    Sweetwater, Florida 33172, United States
    Recruiting
    • Edward Gonzalez · Principal investigator
  • Keenova Site-006
    Salt Lake City, Utah 84107, United States
    Recruiting
    • Clark Larsen · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Dec 2028, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 29, 2026
StartActual
Oct 15, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
4 sites added — first site in United States
Show 4 added (4 United States)
  • Keenova Site-008 · Tarzana, United States
  • Keenova Site-004 · Pinellas Park, United States
  • Keenova Site-007 · Sweetwater, United States
  • Keenova Site-006 · Salt Lake City, United States
Nov 16, 2026
Start date
Oct 11, 2026→Oct 15, 2026 (actual)
Nov 16, 2026
Registered
First appeared on the registry
Sep 29, 2026
Show all 2 updates
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    4 sites added — first site in United States
    Show 4 added (4 United States)
    • Keenova Site-008 · Tarzana, United States
    • Keenova Site-004 · Pinellas Park, United States
    • Keenova Site-007 · Sweetwater, United States
    • Keenova Site-006 · Salt Lake City, United States
    Start date Oct 11, 2026→Oct 15, 2026 (now actual)
    + 1 other change: verification date
  2. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07846280
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Oct 15, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Clinical Operations
Contact
clinicaltrials@endo.com
800-462-3636
Medical Director, MD
study director · Endo USA Inc., a Keenova Therapeutics Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion